C
Abdominal obesity (central adiposity)
Anthropometric & Body CompositionPhysical parameterriskmodifiable
18
evidence score
Also known as: abdominal obesity, obesity by abdominal fat
PREVENT status
Not a PREVENT input variable.
Causal support
trial evidence
Score components
lit volume: 3meta-analyses: 6trials: 9genetic: 0MR bonus:
References (1)
1 meta-analyses / systematic reviews- METAMeta-analysis of psoriasis, cardiovascular disease, and associated risk factors. — Journal of the American Academy of Dermatology 2013 · PMID 24238156
Clinical trials (7)
| NCT | Title | Status | Type | Interventions |
|---|---|---|---|---|
| NCT05032001 | ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT MEASURED BY BIOIMPEDANCE IN TYPE 2 DIABETES PATIENTS. Pilot Study. | UNKNOWN | INTERVENTIONAL | Biguanide, DPP4 inhibitors, SGLT2 inhibitors |
| NCT01632592 | Abdominal Obesity, Cardiovascular Inflammation, and Effects of a Growth Hormone Releasing Hormone Analogue to Reduce Inflammation | WITHDRAWN | INTERVENTIONAL | Tesamorelin, Placebo |
| NCT01208558 | Whole Grain Versus no Grain With or Without Physiotherapy-promoted Exercise for Waist Loss | COMPLETED | INTERVENTIONAL | Diet A, Diet B, Physiotherapy |
| NCT00498433 | Part 1: An Open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin- Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity. Part 2: A Randomized, Double Blind, 12-weeks Parallel Group Study to Compare Effects of Aliskiren 300 mg and Amlodipine 5 mg on the RAS and Lipid/Carbohydrate Metabolism in Fat and Skeletal Muscle of Hypertensive Patients With Abdominal Obesity | TERMINATED | INTERVENTIONAL | Aliskiren, Amlodipine, Placebo of Aliskiren |
| NCT00408148 | A Randomized, Double-blind, Two Arm, Parallel, Placebo Controlled Study of Rimonabant 20 mg Effect on High Density Lipoprotein Kinetics in Patients With Abdominal Obesity and Additional Cardiometabolic Risk Factors | TERMINATED | INTERVENTIONAL | Placebo, Rimonabant |
| NCT01216956 | Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia | COMPLETED | INTERVENTIONAL | Extended-release nicotinic acid versus placebo |
| NCT07022691 | The Association Between Abdominal Obesity, Gluteal Muscles Strength and Endurance in Young and Middle-aged Adults. | ACTIVE NOT RECRUITING | OBSERVATIONAL | Lafayette dynamometer: |
Genetic associations (0)
None linked.